eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..treatment delays are also causing needless anxiety and distress to patients as well as putting lives at serious risk..
richard lipton, md, director, montefiore headache center; edwin s. lowe professor and vice chairman of neurology, albert einstein college of medicine..white house to ban federal funds for clinics that discuss abortion with patients : the two-way.